Table 2.
List of drugs used in T2DM
| S. no | Plant/drug | Extract/compound | Mechanism of action | Organ function | Findings | Recommended/not recommended | Reference | 
|---|---|---|---|---|---|---|---|
| 1 | Moringa oleifera | Moringa seeds | Lessening the expression of iNOS, IL-1β, NO, TNF-α | Liver | ↓plasma glucose levels, HbA1c | Recommended | [113] | 
| 2 | Garcinia macrophylla | 5,7,4′,5″,7″,3‴,4‴-heptahydroxyflavanone [3–6″] flavones | Antibacterial, antioxidant, and anti-T2DM | - | ↓ glucose level | Recommended | [114] | 
| 3 | Albendazole lansoprazole | - | Activation of AMPK and PPAR pathways and incretin-like effect | - | ↑ glucose, HbA1c, triglyceride, LDL, leptin ↓insulin and HOMA-β | Recommended | [115] | 
| 4 | Remogliflozin etabonate (100 mg and 250 mg) | - | SGLT2 inhibition improves urinary glucose excretion thereby decreases blood glucose levels | ↓ glucose levels | Recommended | [116] | |
| 5 | Metformin hydrochloride | - | Lessens intestinal glucose absorption, declines hepatic glucose production, increases insulin sensitivity | Liver | ↓HbA1c levels, FBG, and weight loss | Recommended | [117] | 
| 6 | Remogliflozin metformin teneligliptin | - | - | - | ↓glucose levels, weight | Recommended | [118] | 
| 7 | Rhizoma coptidis | Berberine and polyphenols | Improves β cell dysfunction | Liver adipose tissues | ↓IL-6, TNFα ↑islet cell viability | Recommended | [119] | 
| 8 | Alkaline and flavone category compounds | MAPK1, STAT3, INSR, and 38 signalling pathways | - | Insulin resistance | Recommended | [120] | |
| 9 | Morus alba | Chlorogenic acid, isoquercitrin, and quercitrin | - | - | Glucose absorption, insulin secretion, antioxidant, anti-inflammatory, antihyperglycemic, and antihyperlipidemic activities, declined obesity | Recommended | [121] | 
| 10 | Zingiber officinale | - | - | Heart | ↑diastole function and blood pressure ↓ HbA1c, triglycerides | Recommended | [122] | 
| 11 | Glargine/lixisenatide | - | GLP-1 RA, control postprandial glucose improved β-cell function | - | ↓ HbA1c, weight gain ↓ glucose levels | Recommended | [123] | 
| 12 | Gegen Qinlian decoction berberine | - | Proinflammatory cytokines Nfkb1, Stat1, and Ifnrg1 | Pancreas | Enriched gut microflora ↓ glucose levels | - | [124] | 
| 13 | Gegen Qinlian decoction (meta-analysis study) | - | - | Pancreas | ↓ glucose levels ↑islet function ↓insulin resistance and sensitivity indexes | A need for clinical prognosis and islet function | [125] | 
| 14 | Huanglian Jiedu decoction | Decoction has Huanglian, Huangqin, Huangbo, and Zhizi mixture | Targets AKT1, IL-6, FOS, VEGFA, CASP3 | Pancreas | ↓ glucose levels, HbA1c | Recommended | [126] | 
| 15 | - | Enhance GLUT4, INSR, MAPK1 | - | Improve in fasting glucose level, lipid level, insulin sensitivity index | Recommended | [127] | |
| 16 | Nigella sativa (meta-analysis study) | Thymol, thymohydroquinone, dithymoquinone, nigellone, alpha-hederin, flavonoids, and fatty acids | Antidiabetic, antioxidant, anticancer, hypolipidemic, and anti-inflammatory properties | - | ↓ HbA1c, glucose level, insulin resistance | Recommended | [128] | 
| 17 | Metformin with Chinese traditional medicine | - | - | - | Lessened the hyperglycemia, altered gut microflora, improved insulin resistance | Recommended | [129] | 
| 18 | GLP-1RAs and oral anti-diabetic drugs (meta-analysis) | - | - | Heart | Improvement in left ventricular diastolic function | Recommended | [130] | 
| 19 | GLP-1 RA and SGLT-2i (meta-analysis) | - | - | Pancreas | 5 studies—GLP-1 RA showed decreasing effect in cardiovascular complications, glucose reduction | Recommended | [131] | 
| 20 | Metformin and DDP-4 inhibitors | - | AMPK pathway activation, NFK-β, and mTOR suppression | - | Adverse outcome from COVID-19 | Not recommended | [132] | 
| 21 | Statin, fibrates, and its combination | - | - | - | ↓lipid levels | Recommended | [133] | 
| 22 | Incretin, DDP-4 inhibitors, and GLP-1 RA | - | - | - | ↓ HbA1c | Recommended | [134] | 
| 23 | Anti-hyperglycaemic therapies (GLP-1 RA and SGLT2i) | - | - | - | No change in HbA1c levels | Recommended | [135] | 
| 24 | Metformin (meta-analysis) | - | - | - | ↓ HbA1c ↓ glucose levels | Recommended | [136] | 
| 25 | Aspirin and statin | - | - | Heart | ↓cardiovascular complications in T2DM | Recommended | [133] | 
| 26 | Tofogliflozin with DDP-4 inhibitors | - | - | Pancreas | ↓postprandial glucose | Recommended | [137] | 
| 27 | Momordica charantia | - | - | Pancreas | ↑insulin secretion ↓glucose uptake | Recommended | [138, 139] | 
| 28 | Metformin | - | - | Pancreas | ↑epigenetic markers | Recommended for diagnosis | [140] | 
| 29 | Chenpi | 5-OH PMFs | Antidigestive and anti-inflammatory AMPK activation | ↓hepatic steatosis ↓glucose levels | Recommended | [141] | |
| 30 | Aloe vera | - | - | - | ↓glucose levels | Recommended | [142] | 
| 31 | Berberine | - | - | Pancreas | ↓ HbA1c levels ↓ cholesterol and triglyceride ↑insulin secretion | Recommended | [143] | 
| 32 | Pueraria lobata (meta-analysis) | - | - | Pancreas | Anti-diabetic activity | Recommended | [144] | 
| 33 | SGLT-2i and GLP-1 RA | - | - | Heart | ↓cardiorenal problems, stroke | Recommended | [145] | 
| 34 | - | - | Heart kidney | ↓renal risk No significance in cardio condition | Recommended | [146, 147] | |
| 35 | Sulfonylureas, DPP-4 inhibitors, meglitinides | - | - | Heart | ↑myocardium infection | Recommended | [148] | 
| 36 | Acupuncture with Chinese herbal medicine (meta-analysis) | - | ↓glucose levels ↑ insulin sensitivity and resistance | Recommended | [149] | ||
| 37 | Ipragliflozin (meta-analysis) | - | - | - | ↑ genital infection No significance in glucose level | Not recommended | [150] | 
| 38 | Ginseng supplementation | - | - | - | ↑fasting glucose, postprandial insulin, and HOMA-IR Lipid levels were altered | Recommended | [151] | 
| 39 | Shenqi Jiangtang Granules Baihu Jia Renshen Decoction Tianqi Jiangtang Capsule (meta-analysis) | - | - | Pancreas | ↓hypoglycemia levels | Recommended | [152–154] | 
| 40 | Chinese tradition medicine vs. Western medicine (meta-analysis) | - | - | Pancreas | Traditional medicine showed enhanced insulin sensitivity, decreasing body weight, protects from β cells | Recommended | [155] | 
| 41 | Cotadutide (meta-analysis) | - | - | Pancreas | ↓glucose levels, HbA1c and body weight | Recommended | [156] | 
| 42 | SGD | - | Influences PI3K-Akt, AMPK, and PPAR | Pancreas | ↓ glucose levels and lipid levels ↓ | Recommended | [157] | 
| 43 | Sancai powder | - | - | Pancreas | ↓glucose levels, HbA1c, lipid levels | Recommended | [117] | 
| 44 | Zhimu-Huangbai herb pair | - | - | Pancreas | ↓glucose levels | Recommended | [158] | 
| 45 | Naoxintong capsule | - | Arachidonic acid metabolism, fatty acid β-oxidation, and glycerophospholipid metabolism | Pancreas | ↓hyperlipidemia, hyperglycemia, myocardial infarction, insulin resistance | Recommended | [159, p. 20] | 
| 46 | Pioglitazone and canagliflozin | - | - | - | ↓ glucose levels, lipid levels, HbA1c | Recommended | [160] | 
| 47 | Canagliflozin | - | - | Kidney | ↑ renal oxygen in T2DM | Recommended | [161] | 
| 48 | Pine bark extract | - | - | Pancreas | ↓ HbA1c, VCAM-1, cholesterol levels, UACR | Recommended | [162] | 
| 49 | Jinlida granules | - | - | Pancreas | ↓ HbA1c and glucose levels | Recommended | [163] | 
iNOS, inducible nitric oxide synthase; IL-1β, interleukin-1 beta; NO, nitric oxide; TNF-α, tumour necrosis factor alpha; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus; LDL, low density cholesterol; HOMA-β, homeostasis model assessment of β-cell function; AMPK, adenosine 5′ -monophosphate activated protein kinase; PPAR, peroxisome proliferator-activated receptor; SGLT-2, sodium glucose co-transporter-2; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; FBG, fasting blood glucose; GLP-1 RA, glucagon-like peptide 1 receptor agonists; DDP-4, dipeptidyl peptidase-4 inhibitors; NFK-β, nuclear factor kappa B; mTOR, mammalian target of rapamycin; COVID-19, coronavirus disease-19; 5-OH PMFs, 5-demethylated poly methoxy flavones; HOMA-IR, homeostatic model assessment of insulin resistance; SGD, Shengmai-Yin and Ganmai dazao decoction; VCAM-1, vascular cell adhesion molecule 1; UACR, urinary albumin-to-creatinine ratio; PPAR, peroxisome proliferator-activated receptors; P13K-Akt, phosphatidylinositol 3-kinase-protein kinase B; GLUT4, glucose transporter type 4; INSR, insulin receptor; MAPK1, mitogen-activated protein kinase 1; IL-6, interleukin-6; FOS, Fos proto-oncogene; AP-1, transcription factor subunit; VEGFA, vascular endothelial growth factor A; CASP3, caspase 3; Stat1, signal transducer and activator of transcription 1; Ifngr1, interferon gamma receptor 1; STAT3, signal transducer and activator of transcription 3